Lucentis
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Nonproliferative Diabetic Retinopathy
Conditions
Nonproliferative Diabetic Retinopathy
Trial Timeline
Aug 1, 2016 → Dec 1, 2019
NCT ID
NCT02834663About Lucentis
Lucentis is a approved stage product being developed by Novartis for Nonproliferative Diabetic Retinopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT02834663. Target conditions include Nonproliferative Diabetic Retinopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02834663 | Approved | Completed |
| NCT04847895 | Pre-clinical | Completed |
Competing Products
3 competing products in Nonproliferative Diabetic Retinopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intravitreal aflibercept injection [IAI] + Sham | Regeneron Pharmaceuticals | Phase 3 | 76 |
| EYP-1901 | EyePoint Pharmaceuticals | Phase 2 | 47 |
| AKB-9778 + Placebo | EyePoint Pharmaceuticals | Phase 2 | 47 |